Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00458900

Enrollment

Registered

2007-04-11

Start date

2007-07-31

Completion date

2012-09-30

Last updated

2012-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous administrations. As moxifloxacin is known to have a high oral bioavailability in healthy volunteers, patients are switched to oral or enteral therapy as soon as possible. However, no data on plasma levels for moxifloxacin during such a switch-therapy in IC-patients are available. Therefore, this study aims to evaluate the moxifloxacin-plasma levels and their inter-individual variability during IV to enteral switch therapy in IC-patients.

Interventions

DRUGIV and enteral administration of moxifloxacin

IV and enteral administration of moxifloxacin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* IC patients treated with 400 mg moxifloxacin IV (once a day) that can be switched to enteral administration of 400 mg moxifloxacin. * IV steady state * Hemodynamic stability * Normal enteral feeding without prokinetics * Presence of arterial line * Informed consent * ≥ 18 jaar

Exclusion criteria

* Dialysis patients * Creatinine clearance \< 30 ml/min * Transaminase levels \> 5x upper limit

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetics	2 days	Pharmacokinetics will be followed.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026